Asceneuron

Lausanne, Switzerland

Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease.

$100.0M raised

Jul 2024

Series C

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Asceneuron raised?

Asceneuron has raised $100.0M in total funding. The most recent round was Series C. The last funding was announced in July 2024.

Who are Asceneuron's investors?

Asceneuron's investors include Novo Holdings, OrbiMed, Sofinnova Partners, Kurma Partners, SR One.

Where is Asceneuron headquartered?

Asceneuron is headquartered in Lausanne, Switzerland.

What does Asceneuron do?

Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease.

What stage is Asceneuron at?

Asceneuron is at the Series C stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated July 16, 2024.

MLA

"Asceneuron — Funding & Investors." VCBacked, July 16, 2024, https://www.vcbacked.co/company/asceneuron. Accessed July 2, 2026.

APA

VCBacked. (2024). Asceneuron — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/asceneuron

Wikipedia (cite web)

{{cite web |title=Asceneuron — Funding & Investors |url=https://www.vcbacked.co/company/asceneuron |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated July 16, 2024.